Baricitinib (baricitinib) listed company background and drug research and development status

Baricitinib is a JAK1/JAK2 inhibitor originally developed by Incyte Incyte in the United States. It is used to regulate overactive immune responses in the body. In 2009, Incyte reached a cooperation agreement with Eli Lilly (Eli Lilly), a world-renowned pharmaceutical company, and Eli Lilly will be responsible for its global development, production and marketing. As one of the top ten pharmaceutical companies in the world, Eli Lilly has strong R&D and commercialization capabilities, which provides a strong guarantee for the rapid launch of baricitinib and the simultaneous promotion in multiple countries.

Baricitinib was initially used to treat patients with moderate to severe rheumatoid arthritis (RA) who had an inadequate response to conventional antirheumatic drugs. Clinical trials have shown that the drug can effectively improve joint swelling and pain, and delay the destruction of joint structures. Baricitinib was approved in the EU in 2017 and then in the United States in 2018 The FDA approved the drug, making it another JAK inhibitor that has successfully entered the market after tofacitinib, marking its global recognition for its efficacy in treating inflammatory joint diseases.

After being approved for rheumatoid arthritis, the R&D team of baricitinib continued to expand its indications. Through multiple phase II/III clinical studies, baricitinib has been approved for the treatment of atopic dermatitis (eczema), alopecia areata and other diseases. It has performed particularly well in the field of alopecia areata, becoming the first oral drug approved by the FDA for the treatment of moderate to severe alopecia areata. This development greatly expands its influence in the field of immune dermatology and also proves the potential of its immunomodulatory mechanism in a variety of diseases.

Baricitinib was quickly identified as a potential therapeutic drug during the COVID-19 epidemic. Its immunosuppressive and anti-inflammatory effects help control cytokine storm in patients with severe COVID-19. In large clinical trials completed with support from the National Institutes of Health, baricitinib demonstrated the ability to improve clinical outcomes in critically ill patients and was granted emergency authorization by the FDA. In 2022, the U.S. FDA officially approved its use for the treatment of hospitalized COVID-19 adult patients, making it the first JAK inhibitor used for the treatment of new coronary pneumonia, further consolidating its important position in the field of anti-inflammatory and immune regulation.

Reference materials:https://www.drugs.com/